Microbix Biosystems Inc. (
TSX: MBX, OTCQX: MBXBF,
Microbix®), a life sciences innovator, manufacturer, and
exporter, announces it will be presenting performance results of
its quality assessment products (“
QAPs™”) that
support molecular-diagnostic (“
MDx”)
screening-tests for respiratory viruses at two industry congresses
– “
Labquality Days” in Helsinki, Finland April
20-21, 2022 and “
ECCMID 2022” in Lisbon, Portugal,
April 23-26, 2022.
Labquality Days is an annual international
congress focusing on quality in laboratory medicine and medical
devices. It is sponsored by Labquality Oy, a well-established
Scandinavian clinical-lab proficiency and accreditation authority
that is also a Microbix distribution partner. ECCMID 2022 is the
32nd annual congress organized by the European Society of Clinical
Microbiology and Infectious Diseases.
At these events Microbix will be presenting
performance results of its QAPs for support of MDx tests that
detect multiple respiratory viruses from a single patient-sample.
At Labquality Days, Microbix’s presentation is titled “Microbix’s
Cross-Platform Compatible Respiratory Virus Multiplex Samples for
use as a Quality Management Tool in Laboratory Syndromic Testing.”
At ECCMID, Microbix’s presentation is titled “Respiratory Virus
Multiplex Formulations Desiccated on Copan’s FLOQSwab® for use as
Cross-Platform Compatible EQA Samples and Laboratory Quality
Controls.” Microbix gratefully acknowledges the assistance of its
six collaborator firms in planning and executing these evaluations.
The posters will be available on Microbix’s website
(https://microbix.com) following their presentation.
The two poster presentations detail the
performance of three Microbix “multiplex” QAPs that each support
testing for three to four pathogens, collectively providing quality
management support of testing for 11 common respiratory viruses –
Adenovirus, Enterovirus, Influenza A, Influenza B, Metapneumovirus,
Parainfluenza 2, Parainfluenza 3, Respiratory Syncytial Virus,
Rhinovirus, SARS-CoV-2 (a.k.a., COVID-19), and Seasonal Coronavirus
OC43. Each of these 11 viruses continue to cause widespread human
disease.
These QAPs support the new-generation
diagnostics that simultaneously detect multiple pathogens from a
single patient sample – referred to as “multiplex”
tests. By establishing the precise cause of disease symptoms,
multiplex tests help enable better patient-care while also
providing public health with intelligence on institutional or
community prevalence of pathogens. Multiple new multiplex MDx tests
are also suitable for use outside clinical laboratories – at
point-of-care (“POC”) sites such as clinics or
pharmacies – and thereby provide easier access to care and faster
test results. Microbix “PROCEEDx™FLOQ®” and
“REDx™FLOQ®” QAPs formatted onto Copan® FLOQSwabs®
are ideal for supporting POC tests, as they fully-emulate
test-workflows and are room-temperature stable.
Purchase enquiries for Microbix’s QAPs can be
e-mailed to customer.service@microbix.com.
About Microbix
BiosystemsMicrobix develops proprietary biological
technology solutions for human health and well-being, with over 100
skilled employees and sales now approaching C$ 2.0 million per
month. It makes a wide range of critical biological materials for
the global diagnostics industry, notably antigens for immunoassays
and its laboratory quality assessment products (QAPs™) that support
clinical lab proficiency testing, enable assay development and
validation, or help ensure the quality of clinical diagnostic
workflows. Microbix antigens enable the antibody tests of over 100
international diagnostics companies, while its QAPs are sold to
clinical laboratory accreditation organizations, diagnostics
companies, and clinical laboratories. Microbix QAPs are now
available in over 30 countries, distributed by 1WA (Oneworld
Accuracy Inc.), Alpha-Tec Systems, Inc., Diagnostic International
Distribution SpA., Labquality Oy, The Medical Supply Company of
Ireland, R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc.,
and Thomas Scientific LLC. Microbix is ISO 9001 and 13485
accredited, U.S. FDA registered, Australian TGA registered, Health
Canada establishment licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, discussion of Labquality
Days, Labquality, or ECCMID 2022, the posters or their relevance,
the products of Microbix or its collaborators, Microbix’s business
and business results, goals or outlook, risks associated with
financial results and stability, development projects such as those
referenced in its corporate presentation, regulatory compliance and
approvals, sales to foreign jurisdictions, engineering and
construction, production (including control over costs, quality,
quantity and timeliness of delivery), foreign currency and exchange
rates, maintaining adequate working capital or raising further
capital on acceptable terms or at all, and other similar statements
concerning anticipated future events, conditions or results that
are not historical facts. These statements reflect management’s
current estimates, beliefs, intentions and expectations; they are
not guarantees of future performance. The Company cautions that all
forward-looking information is inherently uncertain and that actual
performance may be affected by a number of material factors, many
of which are beyond the Company’s control. Accordingly, actual
future events, conditions and results may differ materially from
the estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. All statements are made
as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is
under no obligation to update or alter any forward-looking
information.
Please visit https://microbix.com or
www.sedar.com for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Jim Macdonald,Investor RelationsTorrey Hills Capital(858)
456-7300jm@sdthc.com |
Copyright © 2022 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.PROCEEDx™FLOQ® and REDx™FLOQ® are trademarks of
Microbix Biosystems Inc. in collaboration with Copan Italia
S.p.A.Copan®, FLOQ®, and FLOQSwab® are trademarks of Copan Italia
S.p.A.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024